Key Stats for JNJ Stock
- Past-6-Month Performance: 38%
- 52-Week Range: $142 to $252
- Valuation Model Target Price: $288
- Implied Upside: 16%
Value your favorite stocks like Johnson & Johnson with 5 years of analysts’ forecasts using TIKR’s new Valuation Model (It’s free) >>>
What Happened?
Johnson & Johnson stock has climbed about 38% over the past six months, rising to roughly $246 per share as investors priced in accelerating pharmaceutical growth, stronger earnings momentum, and raised 2026 guidance.
The rally has been driven by clear earnings acceleration and improving forward visibility.
This week, the company reported Q4 sales of $24.6 billion, up 7.1%, and adjusted EPS of $2.46, up 20.6%, while full-year sales reached $94.2 billion, up 5.3% despite a significant STELARA biosimilar headwind.
Oncology delivered 21% operational growth for the year, with DARZALEX surpassing $14 billion in annual sales and growing 22%, and TREMFYA surged 65.4% in Q4 to exceed $5 billion for the year.
Management guided 2026 revenue to about $100 billion with adjusted EPS of $11.28 to $11.48, free cash flow of approximately $21 billion, and at least 50 basis points of margin expansion, and CEO Joaquin Duato said the company has “line of sight to double-digit growth by the end of the decade.”
Analyst sentiment has remained constructive following the results as the company exits the peak STELARA erosion phase and pivots toward higher-growth assets in oncology and immunology.
Institutional filings reflected active positioning: Okabena Investment Services raised its stake by 145.7%, Generali Investments increased holdings by 71.4%, and Handelsbanken Fonder boosted its position by 29.9%.
Meanwhile, American Century Companies reduced its stake by 33.5%, Tounjian Advisory Partners cut 36.8%, Close Asset Management trimmed 30%, and DNB Asset Management lowered exposure by 7.6%, suggesting portfolio rebalancing after a strong price run.
With shares now near the upper end of their $142 to $252 52 week range, the six-month surge reflects a re-rating tied to oncology durability, accelerating MedTech growth, and clearer earnings expansion into 2026.
Expectations are now higher, and performance this year will depend on sustaining double-digit oncology momentum, executing immunology launches, and delivering on margin expansion guidance.
See analysts’ growth forecasts and price targets for Johnson & Johnson (It’s free) >>>
Is JNJ Undervalued?
Under valuation assumptions, the stock is modeled using:
- Revenue Growth (CAGR): 6.1%
- Operating Margins: 34.5%
- Exit P/E Multiple: 19x
Revenue is projected to rise from about $100.6 billion in 2026 toward roughly $125.6 billion by 2030, driven primarily by Innovative Medicine growth.
Oncology remains central, supported by continued expansion of DARZALEX and CARVYKTI, while immunology growth is fueled by TREMFYA’s momentum and anticipated new approvals.
MedTech adds incremental upside through Cardiovascular growth, including Abiomed and Shockwave, and new product launches in electrophysiology and robotics.
Operating margins near 34.5% assume continued mix improvement toward higher-margin pharmaceutical revenue, operating leverage following the Kenvue separation, and incremental efficiency gains.
Management expects at least 50 basis points of pretax margin expansion in 2026 despite approximately $500 million of tariff impact, reinforcing earnings durability.
Based on these inputs, the model estimates a target price of $288, implying about 16% upside from current levels.
Johnson & Johnson appears modestly undervalued, with 2026 performance likely driven by oncology durability, pipeline approvals, and sustained margin strength rather than aggressive multiple expansion.
Estimate a company’s fair value instantly (Free with TIKR) >>>
How Much Upside Does JNJ Stock Have From Here?
Investors can estimate Johnson & Johnson potential share price, or what any stock could be worth, in under a minute using TIKR’s New Valuation Model tool.
All it takes is three simple inputs:
- Revenue Growth
- Operating Margins
- Exit P/E Multiple
From there, TIKR calculates the potential share price and total returns under Bull, Base, and Bear scenarios so you can quickly see whether a stock looks undervalued or overvalued.
If you’re not sure what to enter, TIKR automatically fills in each input using analysts’ consensus estimates, giving you a quick, reliable starting point.
See Johnson & Johnson true value, or any stock’s, in under 60 seconds (Free with TIKR) >>>
